New One-Pill Treatment Cures Sleeping Sickness at 96%

Imagine needing just three pills, taken once, to cure a disease that once required hospitalization and complex treatments. That's now the reality for millions of Africans at risk of sleeping sickness.

Acoziborole, a new drug developed by nonprofit DNDi in partnership with the Democratic Republic of Congo, has achieved success rates up to 96% in treating human African trypanosomiasis. The disease, transmitted by infected tsetse flies, has plagued sub-Saharan Africa for generations, particularly affecting impoverished communities.

Dr. Junior Matangila, head of HAT Diseases at DNDi, led the research that made this breakthrough possible. His team tested the drug extensively in the DRC and Guinea between 2016 and 2020, following patients for 18 months after treatment.

Sleeping sickness affects people in two devastating stages. First come headaches, fevers, and swollen lymph nodes. Then the disease attacks the nervous system, causing confusion, coordination problems, and disrupted sleep cycles that gave the illness its common name.

The old treatments required prolonged hospital stays and multiple doses, making them nearly impossible to deliver in remote villages. Many patients simply couldn't access care, leaving them and their communities vulnerable.

Acoziborole changes everything. The single-dose treatment consists of three 320mg tablets that patients take just once. No hospitalization. No multiple trips to distant clinics. Just one treatment session.

The DRC registered the drug in June 2024 after the European Medicines Agency gave its approval. Now the World Health Organization distributes it free of charge to all countries where sleeping sickness is endemic.

The Ripple Effect

The simplicity of this treatment reaches far beyond individual patients. Remote communities that once watched neighbors suffer and die now have access to life-saving medicine delivered directly to them.

Healthcare workers can carry enough treatment for dozens of patients without complex storage requirements or refrigeration. The one-dose approach eliminates the challenge of ensuring patients complete lengthy treatment regimens in areas where returning to a clinic means walking for days.

DNDi has committed to supporting the WHO's ambitious goal of eliminating sleeping sickness as a public health threat by 2030. With Acoziborole now in distribution, that target suddenly looks achievable.

The drug originated from research at Anacor Pharmaceuticals in the United States, then developed through collaboration between DNDi, Sanofi, Scynexis, and Pace University. This international partnership demonstrates how global cooperation can solve health crises affecting the world's most vulnerable populations.

For communities that have lived with sleeping sickness for generations, the future just got dramatically brighter.